Barings 13F: Cuts AstraZeneca (AZN) Stake by $1.8M
Key Points
- Barings reduced its AstraZeneca PLC holdings by 10,967 shares, leaving it with 115,143 shares valued at about $18.8 million.
- AstraZeneca shares traded recently around $171.56, sitting below their 200-day moving average of $180.71 ahead of late October earnings.
- Other large investment managers also adjusted positions in the drug maker, with Ninety One UK cutting its stake by over 1.2 million shares.
Get AstraZeneca PLC text alerts
We text you when insiders, Congress, analysts or big funds move on $AZN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AstraZeneca PLC alert may contain errors. Disclosures
Barings cut its holdings in AstraZeneca PLC by 10,967 shares during the quarter, according to a Form 13F filing with the SEC on October 22, 2026. The adjustment lowered the firm's stake by 8.7% to a total of 115,143 shares. The remaining holdings carried a reported value of $18,755,793 at the time of the filing.
AZN
AstraZeneca PLC
Barings vs. the S&P 500
Hypothetical returns from Barings's disclosed trades, not real profit or advice. How we model this.
What Changed in Barings's AstraZeneca PLC Position
The reduction brought Barings's total share count down from 126,110 shares to 115,143 shares. AstraZeneca shares closed at $172.57 on the October 22, 2026 filing date.
Other Institutional Activity in AstraZeneca PLC
Other large money managers also adjusted their positions in the healthcare firm. Ninety One UK grew its holdings by -1227801 shares, ending with 290,212 shares worth about $47.3 million. Lido Advisors grew its holdings by -89689 shares, ending with 42,073 shares worth about $8.0 million. LMCG Investments grew its holdings by -5258 shares, ending with 0 shares worth about $0.0. Banque Pictet & Cie grew its holdings by 163,549 shares, ending with 350,235 shares worth about $57.1 million. Montrusco Bolton Investments grew its holdings by -42009 shares, ending with 176,054 shares worth about $28.7 million.
AstraZeneca PLC Stock Up 1.8%
AstraZeneca shares recently traded around $171.56 as of October 23, 2026. The stock sits below its 50-day moving average of $162.52 and below its 200-day moving average of $180.71. Over the past 52 weeks, the stock has traded between a low of $153.41 and a high of $212.71.
Recent Earnings
AstraZeneca reported trailing twelve month revenue of $61.37 billion alongside earnings of $6.69 per share.
Dividend
The company pays an annual dividend rate of $3.20 per share.
Analysts Set New Price Targets
On August 24, 2026, CICC initiated coverage with an Outperform rating and a $198.00 price target.
About AstraZeneca PLC
AstraZeneca PLC is a global biopharmaceutical company based in Cambridge, United Kingdom. It focuses on discovering, developing, manufacturing, and commercializing prescription medicines across various therapeutic areas. Institutional portfolio changes offer a look at how major investors position themselves around the company's drug pipeline and commercial performance.
Bottom Line
Investors can watch for the upcoming earnings report scheduled for October 30, 2026, for fresh updates on financial results. Further institutional filings will show how large funds manage their stakes in the months ahead.
Related Filing Alerts
Source: Barings's 13F filing on $AZN (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts